Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Simulations Plus stock

Own Simulations Plus stock in just a few minutes.

Simulations Plus, Inc is a health information services business based in the US. Simulations Plus shares (SLP) are listed on the NASDAQ and all prices are listed in US Dollars. Simulations Plus employs 129 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Simulations Plus

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – SLP – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Simulations Plus share price

Use our graph to track the performance of SLP stocks over time.

Simulations Plus shares at a glance

Information last updated 2021-04-23.
52-week range$36.06 - $90.92
50-day moving average $64.33
200-day moving average $69.03
Wall St. target price$84.67
PE ratio 127.7037
Dividend yield $0.24 (0.36%)
Earnings per share (TTM) $0.54

Buy Simulations Plus shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Simulations Plus stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Simulations Plus under- or over-valued?

Valuing Simulations Plus stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Simulations Plus's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Simulations Plus's P/E ratio

Simulations Plus's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 128x. In other words, Simulations Plus shares trade at around 128x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Simulations Plus's PEG ratio

Simulations Plus's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 7.9132. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Simulations Plus's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Simulations Plus's EBITDA

Simulations Plus's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $15.8 million.

The EBITDA is a measure of a Simulations Plus's overall financial performance and is widely used to measure a its profitability.

Simulations Plus financials

Revenue TTM $45.7 million
Operating margin TTM 30.67%
Gross profit TTM $30.9 million
Return on assets TTM 7.79%
Return on equity TTM 10.69%
Profit margin 23.67%
Book value $8.05
Market capitalisation $1.3 billion

TTM: trailing 12 months

Shorting Simulations Plus shares

There are currently 1.6 million Simulations Plus shares held short by investors – that's known as Simulations Plus's "short interest". This figure is 9.1% up from 1.4 million last month.

There are a few different ways that this level of interest in shorting Simulations Plus shares can be evaluated.

Simulations Plus's "short interest ratio" (SIR)

Simulations Plus's "short interest ratio" (SIR) is the quantity of Simulations Plus shares currently shorted divided by the average quantity of Simulations Plus shares traded daily (recently around 205845.32279315). Simulations Plus's SIR currently stands at 7.59. In other words for every 100,000 Simulations Plus shares traded daily on the market, roughly 7590 shares are currently held short.

However Simulations Plus's short interest can also be evaluated against the total number of Simulations Plus shares, or, against the total number of tradable Simulations Plus shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Simulations Plus's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Simulations Plus shares in existence, roughly 80 shares are currently held short) or 0.1027% of the tradable shares (for every 100,000 tradable Simulations Plus shares, roughly 103 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Simulations Plus.

Find out more about how you can short Simulations Plus stock.

Simulations Plus share dividends


Dividend payout ratio: 44.44% of net profits

Recently Simulations Plus has paid out, on average, around 44.44% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.36% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Simulations Plus shareholders could enjoy a 0.36% return on their shares, in the form of dividend payments. In Simulations Plus's case, that would currently equate to about $0.24 per share.

While Simulations Plus's payout ratio might seem fairly standard, it's worth remembering that Simulations Plus may be investing much of the rest of its net profits in future growth.

Simulations Plus's most recent dividend payout was on 2 May 2021. The latest dividend was paid out to all shareholders who bought their shares by 22 April 2021 (the "ex-dividend date").

Have Simulations Plus's shares ever split?

Simulations Plus's shares were split on a 2:1 basis on 1 October 2007. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Simulations Plus shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Simulations Plus shares which in turn could have impacted Simulations Plus's share price.

Simulations Plus share price volatility

Over the last 12 months, Simulations Plus's shares have ranged in value from as little as $36.057 up to $90.92. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Simulations Plus's is -0.064. This would suggest that Simulations Plus's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Simulations Plus has bucked the trend.

Simulations Plus overview

Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for noncompartmental analysis and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers KIWI, a cloud-based web application to organize, process, maintain, and communicate the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; RENAsym for investigating and predicting drug-induced or acute kidney injury; IPFsym, a software tool to treat or cure idiopathic pulmonary fibrosis; and the Monolix Suite, a solution for modeling and simulation. Further, the company provides population modeling and simulation contract research services; and clinical-pharmacology-based consulting services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site